BRAF and neoplasm: The first of which showed that FR (0.5 mg/kg) treatment of severe combined immunodeficient (SCID) mice with subcutaneously grafted GαqQ209P UM cells resulted in 72% tumor growth inhibition after 14 days, whereas the growth of xenografts established from B-Raf mutant melanoma cells was unaffected [120].